

HOLLIS EDEN PHARMACEUTICALS INC /DE/  
Form 10-Q/A  
September 19, 2005

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

---

**FORM 10-Q/A**

**Amendment No. 1**

(Mark One)

**Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.**

For the quarterly period ended June 30, 2005.

or

**Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.**

For the transition period from \_\_\_\_\_ to \_\_\_\_\_.

Commission File Number:

000-24672

---

**Hollis-Eden Pharmaceuticals, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

**13-3697002**  
(I.R.S. Employer  
Identification No.)

**4435 Eastgate Mall, Suite 400**  
**San Diego, California 92121**  
(address of principal executive offices)

**(858) 587-9333**  
(Registrant's telephone number, including area code)

---

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 (the Exchange Act ) during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  No

Indicate by check mark whether the Registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act).

Yes  No

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.): Yes  No

As of September 12, 2005 there were 20,706,217 shares of Registrant's common stock, \$.01 par value, outstanding.

---

**EXPLANATORY NOTE**

Hollis-Eden Pharmaceuticals, Inc. (the Company) is filing this Amendment No. 1 (the Amendment) to its Quarterly Report on Form 10-Q for the quarter ended June 30, 2005, as filed with the Securities and Exchange Commission on August 5, 2005, to amend and restate the Exhibit Index in Item 6 to file Exhibits 10.42, 10.43, 10.44, 10.45, 10.46 and 10.47. In addition, the Company is also including Exhibits 31.3 and 31.4, as required by the filing of this Amendment. This Amendment, together with the Quarterly Report on Form 10-Q of the Company previously filed for the quarter ended June 30, 2005, constitutes the Quarterly Report on Form 10-Q of the Company for the quarter ended June 30, 2005.

**PART II**

**OTHER INFORMATION**

**ITEM 6. EXHIBITS**

| <b>Number</b> | <b>Description</b>  |
|---------------|---|
| 10.42         | Letter Agreement between Cystic Fibrosis Foundation Therapeutics, Inc. and the Company entered into on December 3, 2003.  |
| 10.43         | Letter Agreement between Cystic Fibrosis Foundation Therapeutics, Inc. and the Company entered into on February 17, 2004. |
| 10.44         | Letter Agreement between Cystic Fibrosis Foundation Therapeutics, Inc. and the Company dated July 12, 2004.               |
| 10.45         | Letter Agreement between Cystic Fibrosis Foundation Therapeutics, Inc. and the Company dated October 19, 2004.            |
| 10.46         | Letter Agreement between Cystic Fibrosis Foundation Therapeutics, Inc. and the Company dated January 6, 2005.             |
| 10.47         | Letter Agreement between Cystic Fibrosis Foundation Therapeutics, Inc. and the Company dated May 16, 2005.                |
| 31.1*         | Rule 13a-14(a)/15d-14(a) Certification of Richard B. Hollis   |
| 31.2*         | Rule 13a-14(a)/15d-14(a) Certification of Daniel D. Burgess   |
| 31.3          | Rule 13a-14(a)/15d-14(a) Certification of Richard B. Hollis   |
| 31.4          | Rule 13a-14(a)/15d-14(a) Certification of Daniel D. Burgess   |
| 32.1*         | Section 1350 Certifications of Richard B. Hollis and Daniel D. Burgess  |

Confidential treatment requested. The redacted portions have been filed separately with the SEC as required by Rule 406 of Regulation C.

\* Previously filed.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Hollis-Eden Pharmaceuticals, Inc.**

Dated September 16, 2005

By: /s/ Daniel D. Burgess  
Daniel D. Burgess, Chief Operating Officer/

Chief Financial Officer (Principal Financial Officer)

Dated September 16, 2005

By: /s/ Robert W. Weber  
Robert W. Weber, Vice President-Controller/

Chief Accounting Officer